Find out more about the overall breast cancer treatment landscape, as biotech companies make progress with different ...

Itovebi, combined with Ibrance and Faslodex, is approved for specific advanced breast cancer cases with PIK3CA mutations ... The Itovebi combination regimen was approved in October 2024 for the ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

NICE has rejected Pfizer’s Ibrance breast cancer drug in first draft guidance, citing the treatment's high cost. The decision confirms the company’s fears that the drug would fare badly under ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Pfizer’s Ibrance has been approved for use by the NHS in Scotland as a second-line treatment for advanced breast cancer after hormonal therapy. The Scottish Medicines Consortium (SMC ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

Globally, approximately 200,000 patients with HR-positive breast cancer receive first-line ... with a CDK4/6 inhibitor — either Ibrance (palbociclib), Kisqali (ribociclib) or Verzenio (abemaciclib) — ...